Skip to content

OASCN Resources | Antimicrobial Monitoring and Adverse Events

The OASCN Resource Bundle was developed by the OASCN Collaborative in 2021-2022. This page provides the relevant didactics (slides and videos), learning points, and literature references from across the OASCN learning sessions related to the topic above.

Relevant Didactics:

  • Antibacterial Drugs for EOS (Jason Sauberan): Slides | Video

Relevant References:

Donnelly PC et al. Ceftriaxone-associated biliary and cardiopulmonary adverse events in neonates: A systematic review of the literature. Pediatr Drugs 2017;19;21.

Van Donge T et al. Key components for antibiotic dose optimization of sepsis in neonates and infants. Front Pediatr 2018;6:325.

Murphy HJ et al. Nephrotoxic medications and acute kidney injury risk factors in the neonatal intensive care unit: clinical challenges for neonatologists and nephrologists. Pediatric Nephrol 2020 Nov;35(11):2077.

Cotton CM et al. Adverse consequences of neonatal antibiotic exposure. Curr Opin Pediatr. 2016;28:141.

Umberto de Rose et al. Therapeutic drug monitoring is a feasible tool to personalize drug administration in neonates using new techniques: an overview on the pharmacokinetics and pharmacodynamics in neonatal age. Int J Mol Sci 2020;21:5898.